Dallas,TX (PRWEB) July 10, 2015 -- The Global Opioid-Induced Constipation Market 2015-2019 report is an inclusive study of prevailing market conditions, incorporating a thorough analysis of the preceding products and effectiveness of Opioid-Induced Constipation treatment. The analysts forecast global opioid-induced constipation market to grow at a cagr of 30.18% over the period 2014-2019.
The Global Opioid-Induced Constipation Market 2015-2019 spreads across 69 pages and provides 23 exhibits to support the research. Complete report available at http://www.reportsnreports.com/reports/403588-global-opioid-induced-constipation-market-2015-2019.html.
The Global Opioid-Induced Constipation Market 2015-2019 explains the lack of awareness amid patients and medical fraternity that has resulted in opting off-label and OTC medications as a widely-chosen treatment option. Various off-label and otc therapies are introduced as a treatment in the global market time-over-time. In 2008, Relistor was approved by US FDA and the EMA as an opioid-induced constipation treatment therapy. This was the first targeted therapy to get an US-FDA and the EMA approval. Also, the recent introduction of peripherally acting mu-opioid receptor antagonists, Movantik, has compelled a significant growth in the market. The drug targets the root cause of the opioid-induced constipation, keeping the analgesic action of the opioid drug intact. Thus, Movantik is getting recognized as the preferred treatment for opioid-induced constipation.
The report drafts the growth prospects of the global opioid-induced constipation market for 2015-2019 based on a thorough analysis of the present market scenarios. Evaluation of the total market size is based on the income engendered from the sale of multiple types of drugs that are used as a treatment options for opioid-induced constipation, the list includes: branded drugs, off-label products, and OTC drugs.
The key players in the Global Opioid-Induced Constipation Market are: AstraZeneca, Takeda Pharmaceutical and Valeant Pharmaceuticals International.
Some of the other Prominent Vendors are: Abbott, Bayer, Boehringer Ingelheim, C.B. Fleet, Cosmo Pharmaceuticals, Daewoong, Daiichi Sankyo, GlaxoSmithKline, Ironwood Pharmaceuticals, Johnson & Johnson, Merck, Mundipharma, Nektar Therapeutics, Pfizer, Progenics Pharmaceuticals, Shionogi, SLA Pharma, Sucampo, Synergy Pharmaceuticals and Theravance.
Purchase a Copy of Global Opioid-Induced Constipation Market 2015-2019 Report at http://www.reportsnreports.com/purchase.aspx?name=403588.
The Global Opioid-Induced Constipation Market 2015-2019 oral drugs are suggested to be a safer and preferred route of drug administration compared to parentally administered drugs, as they are more convenient and trusted source of drug administration. Orally administered drugs like Movantik and Amitiza have helped in increasing patient compliance; the same trend is suggested to be the key-factor to boost the Global Opioid-Induced Constipation Market growth over the forecast span of 2015-2019.
Further, the Global Opioid-Induced Constipation Market 2015-2019 report explains the possible challenges to be faced due to the availability of OTC and off-label drugs restrict the market growth.
Some other key highlights of the report are:
• Market Growth Drivers - Unmet Medical Needs
• Market Challenges - Availability of OTC and Off-label Drugs
• Market Trends - Shift toward Targeted Therapy
• SWOT analysis of the key vendors
Explore Other New Reports by Infiniti Research at http://www.reportsnreports.com/publisher/infiniti-research-limited/.
About US:
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. Call +1 888 391 5441 with your industry research requirements or email, the details on sales at reportsandreports.com.
Ritesh Tiwari, ReportsnReports, http://www.reportsnreports.com/, +1 (888) 391-5441, sales@reportsandreports.com
Share this article